Australia オーストラリア Vol.11(Prime Minister Morrison’s visit to Japan and bilateral summit meeting モリソン豪首相訪日・日豪首脳会談)

Science and Technology 科学技術 Vol.13 / #Coronavirus #コロナウイルス Vol.14(pharmaceutical products 医薬品 Vol.5:drugs 治療薬)

All the below links and excerpts are in English.

Convalescent plasma(回復期血漿療法)に係るリンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

The FDA has authorized convalescent plasma treatment for coronavirus patients – but some scientists worry it’s too soon (08/26/2020) | @businessinsider
During the 1918 Spanish flu pandemic, doctors discovered they could treat sick patients with the blood of those who had already recovered. …
Antibodies develop in plasma, the liquid portion of blood – they’re part of our body’s natural response to a foreign pathogen. So the idea behind the treatment is to help sick people mount an antibody response to the virus by transferring plasma intravenously from those who already have antibodies.
“What we really need are drugs that, when given early, can prevent a symptomatic person from requiring hospitalization or very dramatically diminish the time that they’re symptomatic,” …
… Plasma must be transferred quickly from a donor to a recipient – and both must have compatible blood types. The quantity is also limited, since it depends on blood donations. …
A national study of 35,000 hospitalized coronavirus patients, which is still awaiting peer review, found that patients less than 80 years old who weren’t on a respirator and received plasma containing high levels of antibodies within three days of their diagnosis had a 35% lower mortality rate than those who were treated four or more days after their diagnosis.
The process of creating hyperimmune globulin involves pooling plasma from recovered patients and heat-treating it so that any remaining pathogens get destroyed. The result is a vial of medicine with consistent antibody levels that can easily be administered to patients. The drug focuses on the most common antibody found in blood ? immunoglobulin G (IgG) – which usually confers long-term immunity.
… The Mount Sinai Hospital … working with Emergent BioSolutions, a Maryland-based biopharmaceutical company, to develop a hyperimmune globulin product. …
… “The Fight Is In Us” … The coalition hopes to secure regulatory approval from the FDA by the end of 2020. …

Why we don’t know if convalescent plasma works to treat Covid-19 (08/29/2020) | @qz
… “There’s no money to be made in plasma,” says Jeffrey Henderson, a physician and infectious disease researcher at Washington University St. Louis. Because it’s a biological product, it can’t be patented or sold for a profit. As a result, no single research group or company has funded a large, randomized controlled trial of plasma, the highest standard of clinical evidence. …
It isn’t cheap: Between 2012 and 2018, the median cost of bringing a drug to market was $985 million, about $19 million of which goes to clinical research. Typically, drug companies are happy to invest. Once their product is approved, they can sell it at a price that makes up for the loss (and then some). …
…expanded access program (EAP), a network spearheaded by researchers at the Mayo Clinic in Rochester, Minnesota…
… Eventually, the EAP program got some funding from the US Biomedical Advanced Research and Development Authority…
…Albert Einstein College of Medicine in New York…

Takeda, CSL-led alliance starts scaling up production of COVID-19 plasma therapy as phase 3 kicks off: report (10/13/2020) | @fiercepharma
… The clinical batches were produced at Takeda’s U.S. facility in Georgia and CSL’s site in Bern, Switzerland. The National Institute of Allergy and Infectious Diseases in the U.S. is running the trial. …
Eli Lilly and Regeneron have reported encouraging results for their antibody cocktails, each of which combines two synthetic monoclonal antibodies. While those products have less antibody variety, they only used donated plasma to help identify the antibodies with the most promise in fighting COVID. …

DOD Awards $750,000 to Plasma Technologies, LLC for Manufacturing of Convalescent Plasma Products Using a Novel Process in Support of the U.S. COVID-19 Response (08/17/2020) | DOD
… The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) partnered with HHS and the Army Contracting Command – Aberdeen Proving Ground (ACC-APG), to select Plasma Technologies, LLC for this cooperative agreement. Plasma Technologies, LLC, a plasma biologics technology company, is located in Charleston, South Carolina. …

Plasma Therapy Global Market Report 2020-30: Covid 19 Growth and Change (07/30/2020) | CISION
Major players in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex, Inc., Biotest AG, China Biologic Products Holdings, Inc., DePuy Synthes Companies, CSL Limited, Grifols, S.A., Octapharma, and Terumo BCT, Inc. …
The global plasma therapy market is expected to grow from $187.67 million in 2019 to $246.95 million in 2020 at a compound annual growth rate (CAGR) of 31.6%. The growth is mainly attributed to the COVID-19 outbreak and the urgent need to treat a growing number of cases. …
… In March 2020, Takeda Pharmaceutical Company Limited has initiated a plasma-therapy, Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), which is termed as TAK-888 for treating COVID-19. The TAK-888 utilizes the plasma collected from convalescent donors who have been cured of COVID-19 and is administered to the patient suffering from COVID-19.

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration (05/07/2020) | @TakedaPharma
… In addition to those announced at its inception – Biotest, BPL, CSL Behring, LFB, Octapharma and Takeda – the Alliance welcomes new industry members ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. …
In parallel, the Alliance has confirmed it will work with the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH to test the safety, tolerability and efficacy of the hyperimmune therapy in adult patients with COVID-19. This global study is currently anticipated to start in the summer…
“Hyperimmune globulin therapy has the potential to be one of the earliest treatment options for COVID-19, and we look forward to working with NIAID and health authorities to bring this therapy to patients as early as possible,” …
… To amplify awareness, the Alliance has gained support from large organizations outside of the plasma industry. Examples of those offering resources to the Alliance include Microsoft and Uber Health. Microsoft is providing technology support, including the Alliance website and the Plasmabot for donor recruitment. The Plasmabot streamlines the process for a potential donor to quickly gain information about their nearest collection center from across the member network. In parallel, Uber Health has agreed to donate 25,000 round-trip rides to transport potentially eligible donors to and from plasma collection centers. …

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy (04/06/2020) | @TakedaPharma
Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine…

Trump admin funds plasma company based in owner’s condo (02/11/2020) | @ABCNews
Plasma Technologies LLC, Pepcid, ApiJect Systems America, Novavax
ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on FOX40 and Other Local News Outlets (04/24/2020) | @biospace
Takeda, Other Firms Test Covid-19 Convalescent-Plasma Treatment: NIH funds study of high antibody concentrations combined with the antiviral remdesivir (10/08/2020) | @WSJ

Australia オーストラリア Vol.10(pharmaceutical corporations 製薬会社)

All the below links and tweets are in English.

取り急ぎ以下貼っておきます。

CSL(豪)の子会社
Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29
UK Vol.173 (pharmaceutical corporations: Seqirus) / Australia Vol.30

上記リンク内に無い本日までのツイート

ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの

World 世界情勢等 Vol.7

All the below links are in English.

取り急ぎ以下貼っておきます。

World Vol.51
World Vol.50
World Vol.49
World Vol.48
World Vol.47
World Vol.46
World Vol.45
World Vol.44
World Vol.43
World Vol.42
World Vol.41

Science and Technology 科学技術 Vol.10 / #Coronavirus #コロナウイルス Vol.12(pharmaceutical products 医薬品 Vol.3:vaccines ワクチン)

All the below links and excerpts are in English.

標記関連リンクと当方作成の一部抜粋を取り急ぎ以下のとおり貼っておきます。
(The below Vaccine Tracker is from @nytimes.)

Coronavirus_Vaccine-Tracker-nytimes
Coronavirus Vaccine Tracker (10/24/2020) | @nytimes
〇 Genetic Vaccines – Vaccines that deliver…coronavirus’s own genes into our cells to provoke an immune response.
• Moderna & National Institutes of Health [PHASE 3] mRNA
…planned to wait until a significant number of volunteers became sick with Covid-19 and then see how many had been vaccinated. It may take till the end of 2020 or early 2021 to reach the necessary numbers.
• BioNTech & Pfizer & Fosun Pharma (China) [PHASE 2 & 3] mRNA
… Pfizer and BioNTech would not apply for an emergency use authorization before late November at the earliest. …
…will have to be chilled to minus 80 degrees Celsius (minus 112 degrees Fahrenheit) until it’s ready to be injected.
• Zydus Cadila (India) [PHASE 2] DNA-based
• CureVac (Germany) [PHASE 2] mRNA
• Imperial College London (UK) & Morningside Ventures (UK) [PHASE 1 & 2] “self-amplifying” RNA
• AnGes (Japan) & Osaka University (Japan) & Takara Bio (Japan) [PHASE 1 & 2] DNA-based
• Arcturus Therapeutics (CA) & Duke-NUS Medical School (Singapore) [PHASE 1 & 2] mRNA
• Inovio (PA) [PHASE 1] DNA-based
• Genexine (South Korea) [PHASE 1] DNA-based
• Academy of Military Medical Sciences (China) & Suzhou Abogen Biosciences (China) & Walvax Biotechnology (China) [PHASE 1] mRNA-based
• Chulalongkorn University (Thailand) & Chula Vaccine Research Center (Thailand) [PHASE 1] mRNA-based
• Entos Pharmaceuticals (Canada) [PHASE 1] DNA
• Sanofi (France) & Translate Bio (MA) [PRECLINICAL] mRNA

〇 Viral Vector Vaccines – Vaccines that contain viruses engineered to carry coronavirus genes. …
• CanSino Biologics (China) & Academy of Military Medical Sciences (China) [PHASE 3]
• Gamaleya Research Institute (Russia) [PHASE 3]
• Johnson&Johnson & Beth Israel Deaconess Medical Center (MA) [PHASE 3]
• AstraZeneca & University of Oxford [PHASE 2 & 3]
ReiThera (Italy) & Lazzaro Spallanzani National Institute for Infectious Diseases (Italy);Vaxart (CA);Merck & Themis Bioscience (Austria) & Institut Pasteur (France);German Center for Infection Research (Germany);Merck & IAVI (NY);ImmunityBio (CA);Novartis …
〇 Protein-Based Vaccines – Vaccines that contain coronavirus proteins but no genetic material. …
• Novavax [PHASE 3]
• Anhui Zhifei Longcom (China) & Chinese Academy of Medical Sciences (China) [PHASE 2]
Finlay Vaccine Institute (Cuba);Vector Institute (Russia);Sanofi & GSK、SpyBiotech (UK);Clover Biopharmaceuticals (China) & GSK & Dynavax (CA); University of Queensland (Australia) & CSL (Australia);Medicago (Canada) & GSK & Dynavax;Vaxine (Australia);Kentucky BioProcessing (KY);Medigen (Taiwan) & Dynavax;Adimmune (Taiwan);COVAXX (NY) …
〇 Inactivated or Attenuated Coronavirus Vaccines – Vaccines created from weakened coronaviruses…
• Wuhan Institute of Biological Products (China) [PHASE 3]
• Sinopharm (China) [PHASE 3]
• Sinovac Biotech (China) [PHASE 3]
• Indian Council of Medical Research (India) & National Institute of Virology (India) & Bharat Biotech (India) [PHASE 3]
…..

Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume: Investigators found the unexplained illnesses in both trials appeared unconnected to the vaccines (10/24/2020) | @washingtonpost
… In the Johnson & Johnson trial, which was paused on Oct. 12, a man who received a vaccination suffered a stroke that may have been triggered by an infection. To conclude it was not likely to be related to the shot, investigators probed not only the medical details of the event, but also examined a safety database of 100,000 people who have received vaccines that use the same underlying technology. …
… The company is testing the only vaccine that aims to protect people with a single shot; other prospective vaccines require a return visit and second shot three to four weeks after the first to trigger a protective immune response.
It was the second late-stage vaccine trial put on hold in recent weeks; the vaccine being developed by AstraZeneca and the University of Oxford was halted on Sept. 6 after a British participant developed a neurological problem. …
… Carlos del Rio, an infectious diseases physician at Emory University School of Medicine. “As long as the data and safety monitoring board has reviewed the data and says its OK to proceed, we proceed.”
… William Hartman, a principal investigator of the AstraZeneca trial at the University of Wisconsin Hospital and Clinics. “It is too soon to tell whether participant enthusiasm will approach what it was prior to the pause. …

Covid: More coronavirus vaccine trials in Wales ‘within weeks’ (24/10/2020) | @BBC

Rush for results could lead to inferior Covid vaccine, say scientists (25/10/2020) | @guardian

Dozens of COVID-19 vaccines are in development. Here are the ones to follow. : Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond. (10/13/2020) | @NatGeo
• Novavax (MD) NVX-CoV2373
• Johnson & Johnson (NJ) JNJ-78436735
• Moderna Therapeutics (MA) mRNA-1273
• Pfizer (NY) & BioNTech (Germany) BNT162b2
• University of Oxford (UK) & AstraZeneca (UK) ChAdOx1 nCoV-19
• Sinovac (China) & Butantan (Brazil) CoronaVac
• Sinopharm (China) & Wuhan Institute of Biological Products (China) None
• Murdoch Children’s Research Institute (Australia) & University of Melbourne (Australia) Bacillus Calmette-Guerin BRACE trial
• CanSino Biologics (China) Ad5-nCoV
• The Gamaleya National Center of Epidemiology and Microbiology (Russia) Sputnik V

Recent articles about Japan (mainly on new cabinet) 主に新内閣発足についての日本関連英文記事 Vol.1

All the below tweets are in English.

日本関連ツイートを拾うことは通常どおり特にしない予定でしたが、Reuters社を中心に以前よりは数が増えている感触があるので、前回投稿分以降の日付のものを中心にざぁっとですが拾ってみました。3回に分けて投稿します。
While I have not intended to collect news articles mainly on Japan’s new cabinet, I have come to confirm that there are more articles – mainly by Reuters – related to such issues than before as I have thought. That is why I collected roughly and posted here mainly tweets after the last post (Sep 8). This is the first of the three posts this time.

Australia オーストラリア Vol.9(corporations 企業)

All the below tweets are in English.

ツイッター検索において企業の日本関連について出て来たものを取り急ぎ以下貼っておきます。(大学のツイートについては Vol.8 をご覧ください。)


https://twitter.com/TravelEsquire/status/1091250621972471809


https://twitter.com/farmweekly/status/1172064805559164930


https://twitter.com/AustraliaInJPN/status/784226770979393536


https://twitter.com/_bankista/status/1008888817774972929


https://twitter.com/TimBuckleyIEEFA/status/1126669832823291905


https://twitter.com/aurorastormG3/status/1237812287244611584


https://twitter.com/MarkPlackett1/status/1093997375557853184


https://twitter.com/austal/status/1169501940809527306


https://twitter.com/MatonGuitars/status/1136175430774296576


https://twitter.com/LithiumIonBull/status/1219631155017867266


https://twitter.com/SevenNetwork/status/1153770597291134976

Australia オーストラリア Vol.8(corporations, universities, etc. 企業、大学など)

All the below links and tweets are in English.

取り急ぎ標記につき以下貼っておきます。
Australia Vol.23 (corporations)
Australia Vol.22 (corporations)
Australia Vol.21 (corporations)
Australia Vol.20 (corporations)
Australia Vol.19 (think tanks, banks)
Australia Vol.28 (University of North South Wales)
Australia Vol.27 (University of Sydney)
Australia Vol.26 (University of Queensland)
Australia Vol.25 (Monash University)
Australia Vol.24 (University of Western Australia, University of Adelaide)
Australia Vol.18 (Australian National University, University of Melbourne)

ツイッター検索において大学の日本関連について出て来たもの(企業のツイートについては Vol.9 をご覧ください。)
https://twitter.com/karnfull_en/status/1231708191081353221


https://twitter.com/dfat/status/458385700279160832


https://twitter.com/ANUasiapacific/status/1173132179242508288

Australia オーストラリア Vol.7(2019 federal election results, etc. 総選挙結果など)

All the below links but the below tweets are in English.

まだ結果未確定部分がありますが、取り急ぎ標記につき以下貼っておきます。
Australia Vol.17 (2019 federal election)

cf. Australia オーストラリア Vol.6(states, economy, politics, etc. 各州, 経済, 政治 など)
Trans-Pacific Partnership #TPP Vol.3 (Miscellaneous)
Antarctic Vol.1
など etc.

—–この部分は、5月24日昼頃に追加しました。
Alliances Adrift: Is this the end of America’s Asian alliances? (14/05/2019) | Coral Bell School of Asia Pacific Affairs, ANU College of Asia & the Pacific 以下、一部抜粋。
… In the face of structural change towards a more multipolar Asian security order, however, coupled with unprecedented uncertainties regarding US credibility and resolve in this part of the world, most of the United States’ Asian alliances are arguably looking increasingly brittle.
Leading experts from Australia, the Philippines, Singapore, South Korea and Thailand contributed their views on the nature and trajectory of alliances at a one-day workshop “Alliances Adrift: Is this the end of America’s Asian alliances?”
The workshop held on 23 April 2019 in Singapore …
… ANU participants included Professor Brendan Taylor, Emeritus Professor William Tow and Dr Lauren Richardson. …
Taylor and Tow subsequently visited Manila on 26th April to attend a roundtable discussion on the “Dilemmas of the Indo-Pacific”. They interacted with Philippines officials and scholars at the Asia-Pacific Pathways-sponsored event where they examined the US’ Free and Open Indo-Pacific (FOIP) strategy. …
Emeritus Professor William Tow provided a synoptic review of the Trump administration’s policy in the Indo-Pacific … also tackled catalysts for the FOIP, such as the possibility of an emerging China-containment doctrine by the US, domestic pressures on the Trump administration to have a different foreign policy from Obama, and the complementarity of ideology and geography to operationalise the “America First” rhetoric.
Professor Brendan Taylor discussed Australia’s stakes in the Indo-Pacific, such as its fears of exclusion from the region and economic decline … underscored the conceptual ambiguity and the divergent interests within the Quadrilateral Security Dialogue (between Japan, US, Australia, and India) that may derail future development.
… During the open discussion, participants raised issues such as the feasibility and appropriateness of having a China-containment goal for the Quadrilateral Security Dialogue between Japan, the US, Australia, and India …
Taylor and Tow will bring the discussions and papers from these workshops together by co-editing a special issue in an internationally respected journal planned to appear in early 2020. They will also visit Northeast Asia and the United States later this year to follow up the Singapore session …
——-

以下は、標記と言うよりは、日豪首脳その他を検索して出てくるツイートです。
自由貿易の原則の下での各種の国益最重視 を堅持すれば長期的に国全体としてうまく行く、
客観的で説得力のある理由付けが随時必要である、と考えております。


https://twitter.com/rugbyworldcupjp/status/954249235515387904


https://twitter.com/jmsdf_pao_eng/status/1130361378622005248


https://twitter.com/sarahinthesen8/status/1039393353626841089

Australia オーストラリア Vol.6(states, economy, politics, etc. 各州, 経済, 政治 など)

All the below links are in English.

標記につき取り急ぎ貼っておきます。なお、worldsolutions.work の各ポストは、日付が若干新しくありませんが、内容は最近、大幅に拡充等したものです。

Australia
https://twitter.com/WSjp_insight/status/1111191362509037568

Australia Vol.8 (New South Wales) ニューサウスウェールズ州
Australia Vol.13 (Victoria) ビクトリア州
Australia Vol.12 (Queensland) クイーンズランド州
Australia Vol.10 (South Australia) サウスオーストラリア州
Australia Vol.9 (Western Australia) ウェスタンオーストラリア州
Australia Vol.11 (Tasmania) タスマニア州
Australia Vol.6 (Northern Territory) ノーザンテリトリー(北部特別地域)
Australia Vol.2 (Australian Capital Territory) オーストラリア首都特別地域

Australia Vol.5 (Economy) 経済
Australia Vol.1 (Politics) 政治
Australia Vol.15 / Trans-Pacific Partnership #TPP Vol.2 TPP
Australia Vol.16 / Meat Vol.2 
Australia Vol.7 (Climate change) 気候変動
Australia Vol.14 / Antarctic Vol.2 南極

各州名及びJapanなどを入れて検索して出てきたツイートです。政府に関連するという立場でない弊社としては、現時点で日本の命運を左右する話題ではなく経済動向と不可分である国際情勢等の空気も見えるもの を敢えて外さないことがあってもむしろ良いのではないかと考え、今回は一部その類のものを含めています。
The below tweets are found if you enter such words as states’ names and Japan, etc. As far as our LLC, which is not related to the Government of Japan, has considered, this time it would be rather better to dare not to take off the information which does not affect the fate of Japan as of May 15, and which shows the atmosphere of international affairs inseparably linked to economy.


https://twitter.com/solarcitizens/status/1111147038702333952


https://twitter.com/dfat/status/858205993640927232


https://twitter.com/AusAmbCyber/status/1107747754426589184